Related Experiment Video
Updated: Mar 9, 2026

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
Published on: February 20, 2021
Corilagin ameliorates the extreme inflammatory status in sepsis through TLR4 signaling pathways
Hua-Rong Li1,2, Jie Liu3, Shu-Ling Zhang1
1Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
Background:
Sepsis is one of the serious disorders in clinical practice. Recent studies found toll-like receptors 4 (TLR4) played an important role in sepsis. In this study, we tried to find the influence of Corilagin on TLR4 signal pathways in vitro and in vivo.
Methods:
The cellular and animal models of sepsis were established by LPS and then interfered with Corilagin. Real-time PCR and western blot were employed to detect the mRNA and protein expressions of TLR4, MyD88, TRIF and TRAF6. ELISA was used to determine the IL-6 and IL-1β levels in supernatant and serum.
Results:
The survival rate was improved in the LPS + Corilagin group, and the mRNA and protein expressions of TLR4, MyD88, TRIF and TRAF6 were significantly decreased than that in the LPS group both in cellular and animal models (P < 0.01). The pro-inflammatory cytokines IL-6 and IL-1β were greatly decreased in the LPS + Corilagin group both in supernatant and serum (P < 0.01).
Conclusions:
Corilagin exerts the anti-inflammatory effects by down-regulating the TLR4 signaling molecules to ameliorate the extreme inflammatory status in sepsis.
Insights
Corilagin reduces inflammation in sepsis by down-regulating toll-like receptor 4 (TLR4) signaling pathways. This natural compound improves survival rates and decreases pro-inflammatory cytokines in cellular and animal models.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Sepsis is a critical clinical disorder with significant mortality.
- Toll-like receptor 4 (TLR4) signaling is implicated in the pathogenesis of sepsis.
- Investigating therapeutic interventions targeting TLR4 is crucial for sepsis management.
Purpose of the Study:
- To investigate the therapeutic potential of Corilagin in sepsis.
- To elucidate the effects of Corilagin on TLR4 signaling pathways in vitro and in vivo.
Main Methods:
- Sepsis models were induced using lipopolysaccharide (LPS) and treated with Corilagin.
- Quantitative real-time PCR and Western blot analyzed gene and protein expression of TLR4, MyD88, TRIF, and TRAF6.
- Enzyme-linked immunosorbent assay (ELISA) measured levels of interleukin-6 (IL-6) and interleukin-1β (IL-1β).
Main Results:
- Corilagin treatment significantly improved survival rates in sepsis models.
- Down-regulation of mRNA and protein expression for TLR4, MyD88, TRIF, and TRAF6 was observed with Corilagin.
- Pro-inflammatory cytokines IL-6 and IL-1β levels were significantly reduced in Corilagin-treated groups.
Conclusions:
- Corilagin demonstrates significant anti-inflammatory effects in sepsis.
- Down-regulation of TLR4 signaling molecules by Corilagin ameliorates excessive inflammation in sepsis.
- Corilagin represents a potential therapeutic agent for sepsis treatment.
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
The JAK-STAT Signaling Pathway
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Regulation of the Unfolded Protein Response

